long term safety of glp-1 drugs have taken the world by storm, helping many people lose 11%–16% their body weight. But a new Cochrane review reveals something surprising: the evidence supporting these blockbuster injections isn't glp-1 long-term use safety The

Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a short-term program that gives eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay per month

This flexibility is a significant advantage, particularly for new users who want to test the service without long-term financial commitment

Telogen effluvium is a condition that pushes an abnormal amount of hair follicles into the telogen phase, leading to more shedding than usual

Keywords: diabetes mellitus, gastric emptying, glucagon-like peptide 1 receptor agonists, major adverse cardiovascular events, obesity, perioperative care Editor's key points